Comparing Pro-Dex (NASDAQ:PDEX) & Femasys (NASDAQ:FEMY)

Pro-Dex (NASDAQ:PDEX) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Profitability

This table compares Pro-Dex and Femasys’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pro-Dex	9.17%	16.74%	9.98%
Femasys	-1,435.77%	-141.49%	-82.30%

Insider & Institutional Ownership

15.3% of Pro-Dex shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 47.5% of Pro-Dex shares are owned by company insiders. Comparatively, 12.3% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for Pro-Dex and Femasys, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pro-Dex	0	0	1	0	3.00
Femasys	0	0	3	0	3.00

Pro-Dex presently has a consensus target price of $52.00, suggesting a potential upside of 6.12%. Femasys has a consensus target price of $10.00, suggesting a potential upside of 809.09%. Given Femasys’ higher possible upside, analysts plainly believe Femasys is more favorable than Pro-Dex.

Volatility & Risk

Pro-Dex has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500. Comparatively, Femasys has a beta of -2.83, suggesting that its stock price is 383% less volatile than the S&P 500.

Valuation & Earnings

This table compares Pro-Dex and Femasys”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pro-Dex	$53.84 million	2.97	$2.13 million	$1.54	31.82
Femasys	$1.07 million	23.54	-$14.25 million	($0.81)	-1.36

Pro-Dex has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Summary

Pro-Dex beats Femasys on 9 of the 13 factors compared between the two stocks.

About Pro-Dex

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

About Femasys

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.